The following abstract presents results of a study conducted by a contract laboratory for the National Toxicology Program. The findings have not been peer reviewed and were not evaluated in accordance with the levels of evidence criteria established by NTP in March 2009. The findings and conclusions for this study should not be construed to represent the views of the NTP or the U.S. Government.
Thalidomide is presently being suggested in the treatment of immune-related diseases, in particular, treatment of acquired immune deficiency syndrome patients. The purpose of these studies was to determine the doses of TLM and the route of administration for use in the protocol studies.
These studies were conducted in female B6C3F1 mice. The animals were treated with TLM for 14 days either by intraperitoneal injection or gavage. TLM was prepared daily in sterile distilled water.
In the 14-day range-finding study, no difference was observed in the results of the antibody-forming cell response by either route of administration; therefore, intraperitoneal injection was established as the route for the TLM protocol.